Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | TSHR | P16473 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | CDK2 | P24941 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | CDC7 | O00311 | 1/20 | 0.55 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913636 | 0.89 | LMNA (0.65) | LMNAHTTALOX15SMN1; SMN2TSHR | |
| SCHEMBL30523385 | 0.88 | LMNA (0.72) | LMNAHTTALOX15SMN1; SMN2TSHR | |
| SCHEMBL4921198 | 0.88 | LMNA (0.72) | LMNAHTTALOX15SMN1; SMN2TSHR | |
| SCHEMBL2805439 | 0.88 | LMNA (0.64) | LMNAHTTALOX15SMN1; SMN2TSHR | |
| SCHEMBL16147218 | 0.87 | LMNA (0.67) | LMNAHTTALOX15SMN1; SMN2TSHR | |
| SCHEMBL2806282 | 0.86 | HTT (0.62) | LMNAHTTALOX15SMN1; SMN2TSHR | |
| SCHEMBL2810190 | 0.86 | LMNA (0.62) | LMNAHTTALOX15SMN1; SMN2TSHR | |
| SCHEMBL4913694 | 0.86 | LMNA (0.65) | LMNAHTTALOX15SMN1; SMN2TSHR | |
| SCHEMBL4921308 | 0.85 | LMNA (0.64) | LMNAHTTALOX15SMN1; SMN2TSHR | |
| SCHEMBL4917825 | 0.85 | LMNA (0.64) | LMNAHTTALOX15SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203451-B1 | SUBSTITUTED 6-(ALKYLBENZYLAMINO)PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIV PALACKEHO (CZ) | 2014-07-30 | — | — | EP | claimed |
| US-20130130906-A1 | SUBSTITUTED 6-(ALKYLBENZYLAMINO) PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | FREIE UNIVERSITAT BERLIN (DE) | 2013-05-23 | — | — | US | claimed |
| US-20100240537-A1 | Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives | FREIE UNIVERSITAT BERLIN (DE) | 2010-09-23 | — | — | US | claimed |
| EP-2203451-A2 | SUBSTITUTED 6-(ALKYLBENZYLAMINO)PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | Univerzita palackeho V Olomouci (CZ) | 2010-07-07 | — | — | EP | claimed |
| CN-1556808-B | Containing radicals based on N6Cosmetic preparation of heterocyclic compound of-substituted adenine | UZTAF EXPERIMENT PLANT SOC CZ V | 2010-04-28 | — | — | CN | claimed |
| WO-2009043320-A2 | SUBSTITUTED 6-(ALKYLBENZYLAMINO)PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2009-04-09 | — | — | WO | claimed |
| EP-2203451-B1 | SUBSTITUTED 6-(ALKYLBENZYLAMINO)PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIV PALACKEHO (CZ) | 2014-07-30 | — | — | EP | disclosed |
| US-20130130906-A1 | SUBSTITUTED 6-(ALKYLBENZYLAMINO) PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | FREIE UNIVERSITAT BERLIN (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240537-A1 | Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives | FREIE UNIVERSITAT BERLIN (DE) | 2010-09-23 | — | — | US | disclosed |
| EP-2203451-A2 | SUBSTITUTED 6-(ALKYLBENZYLAMINO)PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | Univerzita palackeho V Olomouci (CZ) | 2010-07-07 | — | — | EP | disclosed |
| CN-1556808-B | Containing radicals based on N6Cosmetic preparation of heterocyclic compound of-substituted adenine | UZTAF EXPERIMENT PLANT SOC CZ V | 2010-04-28 | — | — | CN | disclosed |
| WO-2009043320-A2 | SUBSTITUTED 6-(ALKYLBENZYLAMINO)PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130130906-A1 | SUBSTITUTED 6-(ALKYLBENZYLAMINO) PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | ADORA2A, ADORA1, GART | LMNA 3801/4885HTT 4686/4885ALOX15 2544/4885 |
| US-20100240537-A1 | Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives | ADORA2A, P2RY6, P2RY1 | LMNA 4026/4885HTT 4657/4885ALOX15 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.